About us

  • David Redfern

    Chairman

  • Dr Dominique Limet

    CEO

  • Doug Giordano

  • Dr Zhi Hong

  • Abbas Hussain

  • Dr John Keller

  • Dr Rod MacKenzie

  • Ian McCubbin

  • Paul-Peter Tak

  • Dr Dominique Limet

    CEO

  • Bill Collier

    Head of North America

  • Terry Crandall

    Legal Counsel and Company Secretary

  • Dr Manuel Goncalves

    Head of External Affairs and Communications

  • Dr John Pottage

    Chief Scientific and Medical Officer

  • Jacopo Andreose

    Head of International

  • Tim Tordoff

    Head of Europe

  • Mark Cockett

    Vice President, Head of Discovery

  • Gregory Reinaud

    Head of Global Commercial Strategy

  • Jerome Andries

    CFO

  • Jocelyn Brown

    Global Head of HR

 
  • David Redfern

    Chairman

    David Redfern is the Chairman of ViiV Healthcare’s Board. David was appointed as GSK’s Chief Strategy Officer in May 2008 and is responsible for proactive exploration of new business opportunities, strategic planning and dermatology. He is a member of the GSK Corporate Executive Team. Previously, he was Senior Vice President, Northern Europe with responsibility for managing GSK's pharmaceutical businesses in Denmark, Finland, Iceland, Ireland, the Netherlands, Norway, Sweden and Switzerland. David also had overall responsibility for the European HIV business from 2006 to 2008. David joined the company in 1994 from PricewaterhouseCoopers, where he managed a portfolio of audit clients and corporate transactions. He began his career with GSK as Corporate Accounts Manager, and spent 4 years in the Corporate Development team before being appointed Finance Director of European Pharmaceuticals in 1999. He was appointed Senior Vice President & Area Director, Central Europe in 2003, where he successfully led the Central Europe markets through their transition into the EU, and Northern Europe in 2005. David has a Bachelor of Science degree from Bristol University in the UK and is a Chartered Accountant.

  • Dr Dominique Limet

    CEO

    Our CEO is Dr Dominique Limet, former Senior Vice President (SVP) and Head of Personalised Medicine Strategy for GSK.

    Dominique worked for Ciba-Geigy before joining Glaxo Wellcome in France in 1996. He became Chairman and Managing Director in 2000 and, subsequently, General Manager of GSK France. In 2003 he was appointed SVP and Area Director for GSK's pharmaceutical business in Southern & Eastern Europe.

    Dominique holds a Doctorate in Medicine, a specialisation in occupational medicine, and Marketing and Management qualifications earned at INSEAD. At GSK, Dominique served as a member of GSK's Positive Action Steering Committee and was a board member of the GSK France Foundation, which supported a range of HIV/AIDS-related programmes around the world.

  • Doug Giordano

    Doug Giordano is currently a Senior Vice President in Pfizer’s Worldwide Business Development Group, responsible for leading the evaluation, negotiation and execution of product licensing, partnerships and M&A transactions.  Over the past six years, Doug has led teams responsible for Pfizer acquisitions and product licensing transactions including Pfizer’s acquisitions of Wyeth, Icagen, Excaliard, King Pharmaceuticals, FoldRx, Coley, CovX, Encysive and Serenex, and product collaborations announced with various partners including Hisun, Mylan, GlycoMimetics, Bausch & Lomb and Teuto.

    Before joining Pfizer’s Worldwide Business Development group in 2007, Doug held positions of increasing responsibility within Pfizer’s US Pharmaceuticals commercial strategy and business development team.  Doug has been a key contributor to a variety of Pfizer transactions and a variety of innovative US commercialization initiatives including the creation and launch of the Pfizer/Microsoft/IBM collaboration, Amicore and the launch of the Pfizer for Living ShareCard andPfizer Helpful Answers programs.   

    Before his US pharmaceuticals operating role, Doug worked in a mergers and acquisitions role within Pfizer’s Medical Technology Group -- playing a key role in Pfizer’s acquisitions, technology licensing and divestiture activity within medtech.  Prior to his role with the Medical Technology Group, Doug held positions within Pfizer’s US Pharmaceutical Group in finance and global manufacturing.

    Prior to joining Pfizer, Doug was a consultant at Booz, Allen & Hamilton.

    Doug holds a Bachelor’s Degree in Biomedical Engineering from Duke University and an M.B.A. degree from Cornell University’s Johnson School of Business. 

  • Dr Zhi Hong

    Dr Zhi Hong is SVP and Head of the Infectious Diseases Centre of Excellence for Drug Discovery at GSK.

    Prior to joining GSK in 2007, he was Executive Vice President and Chief Scientific Officer of Ardea Biosciences, Inc., a biopharmaceutical company focused on small-molecule drugs to treat viral diseases, cancer and inflammation.

    An inventor on numerous patents and an author of more than 100 research papers, Zhi received his bachelor's degree in Biochemistry from Fudan University in Shanghai and his PhD in Biochemistry from the State University of New York at Buffalo.

  • Abbas Hussain

    Abbas Hussain is President, Emerging Markets at GSK. He joined from Eli Lilly and Company, where he was President, Europe.

    Abbas joined Lilly UK in 1988 before moving to Australia in 1990. Over the following 12 years, he held senior positions for the company in the US, Asia, India, Turkey and Germany. He was appointed European Mid-Size Area Director in 2003 and then Vice President of Europe with specific responsibility for the Western European Mid-Size countries, Africa & Middle East Area/Commonwealth of Independent States and Central & Eastern Europe regions.

    Abbas has a degree in Medicinal Chemistry & Pharmacology from Loughborough University of Technology, UK.

  • Dr John Keller

    Dr John Keller joined Shionogi Inc. in July of 2010 and was appointed as President and Chief Executive Officer and as a member of the Shionogi Inc. Board of Directors in April 2011.

    Immediately prior to joining Shionogi, John was a Partner in SR One, the venture capital group of GlaxoSmithKline. Previously, John served as Executive Vice President and Chief Business Officer of Incyte Corporation, playing a key role in its transformation into a drug discovery and development company and establishing its first major corporate alliance after that transformation. Before Incyte, John had a 16 year tenure at GlaxoSmithKline and its predecessor, SmithKline Beecham, culminating in the position of Vice President, Worldwide Business Development. In that role, he structured numerous licensing agreements with a broad range of partners worldwide, including the agreements originally establishing the Shionogi-GSK (later Shionogi-ViiV Healthcare) joint venture. Earlier positions encompassed R&D strategy, technology licensing, alliance management, public policy, project management, and drug discovery research.

    John holds a Ph.D. in microbiology from Rutgers University and a Bachelors degree in biology from Johns Hopkins University.

  • Dr Rod MacKenzie

    Dr. Rod MacKenzie is Senior Vice President, Head of Pfizer PharmaTherapeutics Research and Development. He oversees an international network of scientists and other pharmaceutical R&D professionals in Research, Pharmaceutical Sciences, Asia R&D, and their functional lines.

    Rod began his career at Pfizer in 1986 as a Research Scientist and worked in many medicinal chemistry programs across various therapeutic areas. Rod is the co-inventor of darifenacin (EnablexTM). He has held a range of posts in the following years, including Senior Vice President, Drug Safety R&D and Comparative Medicine, and Senior Vice President, Head of Worldwide Research.

    Rod graduated from the University of Glasgow with a 1st Class Honors degree in chemistry and completed his PhD at Imperial College, London. He was awarded a NATO Postdoctoral Research Fellowship and spent two years at Columbia University, New York working in the area of molecular recognition.

  • Ian McCubbin

    Ian McCubbin is SVP of Strategy, Logistics and External Supply at GSK.

    He joined GSK's manufacturing and supply business in 1985 and over 16 years held a number of senior production, logistics and continuous improvement roles including Site Director at the Ware manufacturing site in the UK. Ian re-joined GSK in 2006, having held senior operational roles in both Merck Generics and IVAX.

    Ian holds a degree in Pharmacy from Heriot-Watt University, Edinburgh.

  • Paul-Peter Tak

    Paul-Peter Tak received his medical degree cum laude from the Free University in Amsterdam and was trained as an internist, rheumatologist and immunologist at Leiden University Medical Center, where he also received his PhD. He has worked as a scientist at the University of California San Diego for two years. He served as Professor of Medicine and Chair of the Department of Clinical Immunology and Rheumatology at the Academic Medical Centre/University of Amsterdam (AMC) for 12 years. In addition to his work in academia he established a biotech company developing intra-articular gene therapy (Arthrogen b.v.). He has published extensively in peer-reviewed scientific journals.

    Since 2011 he is Senior Vice President and head of the ImmunoInflammation Therapy Area Unit at GlaxoSmithKline and appointed SVP R&D Pipeline in January 2016. He is also co-chair of GSK’s Scientific Review Board, co-chair of the Technology Investment Board, member of the Portfolio Investment Board, member of the Bioelectronics Investment Board, member of the Scientific Advisory Board of Index Life VI (Life Sciences Fund), member of the Board of Directors of ViiV Healthcare and member of the Innovation Board Steering Committee of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

  • Dr Dominique Limet

    CEO

    Our CEO is Dr Dominique Limet, former Senior Vice President (SVP) and Head of Personalised Medicine Strategy for GSK.

    Dominique worked for Ciba-Geigy before joining Glaxo Wellcome in France in 1996. He became Chairman and Managing Director in 2000 and, subsequently, General Manager of GSK France. In 2003 he was appointed SVP and Area Director for GSK's pharmaceutical business in Southern & Eastern Europe.

    Dominique holds a Doctorate in Medicine, a specialisation in occupational medicine, and Marketing and Management qualifications earned at INSEAD. At GSK, Dominique served as a member of GSK's Positive Action Steering Committee and was a board member of the GSK France Foundation, which supported a range of HIV/AIDS-related programmes around the world.

  • Bill Collier

    Head of North America

    Bill Collier is head of the North America region, responsible for the businesses in the US, Canada and Puerto Rico.

    Bill has held a number of Sales and Marketing positions in the UK and in Global Commercial Development. He was also Area Director for Sub Saharan Africa operations (which included marketing and sales responsibility for the HIV product portfolio). In the USA, Bill led the Marketing Analysis and Commercial Support teams through the GlaxoWellcome and SmithKline Beecham merger and was also Senior VP Sales for US Pharmaceuticals. Most recently, Bill has worked in GSK's Office of the CEO coordinating the Support Function Review and supporting launch excellence in GSK Japan.

    Bill gained a BSc Hons in Mathematics and Management Sciences from Manchester University, UK.

  • Terry Crandall

    Legal Counsel and Company Secretary

    Our head Legal Counsel and Company Secretary, Terry Crandall was previously Assistant General Counsel, Sales, Marketing & Managed Care (SMMC) - US Legal Operations, GSK. In this role she was responsible for providing support to HIV products EpzicomCombivir and Trizivir, as well as the HIV sales force.

    In addition, Terry served as lead counsel on Direct-to-Consumer Advertising (DTCA) and represented GSK in the development of the PhRMA Code on DTCA and provided support regarding legislative issues concerning DTCA.

    Terry received BA degrees with Honours in English and Psychology from Bucknell University, Phi Beta Kappa, and her Law degree from the University of North Carolina, Chapel Hill. She is a member of the North Carolina Bar and the Illinois Bar.

  • Dr Manuel Goncalves

    Head of External Affairs and Communications

    Dr Manuel Goncalves is Head of External Affairs and Communications.

    Manuel joined GSK in 1984 as Medical & Regulatory Affairs Director, Portugal. He progressed through a series of commercial roles of increasing seniority in France, the UK and Portugal. He became VP and General Manager of GSK's pharmaceuticals business in Portugal in 1997. In this role, he gained significant experience in working with members of the government and local community on market access, healthcare policy and industry reputation issues while running the commercial business including the HIV product portfolio.

    Manuel is a medical doctor by education and an elected member of the Portuguese Medical Academy and the General Council of Lisbon Public University (Nova).

  • Dr John Pottage

    Chief Scientific and Medical Officer

    Dr John Pottage is our Chief Scientific and Medical Officer. He oversees R&D, Regulatory, Safety and Medical Affairs.

    John is the former SVP, Infectious Diseases Medicine Development Centre for GSK. John previously held senior positions at Vertex Pharmaceuticals and Achillion Pharmaceuticals, where he helped lead a successful IPO in 2006 and led the HIV and HCV development programmes. Before joining the pharmaceutical industry, John was Associate Professor of Internal Medicine in the Section of Infectious Diseases at Rush Medical College in Chicago. While at Rush, he was Director of the Outpatient HIV Centre.

    John is board certified in both Internal Medicine and Infectious Disease. He is the author of more than 50 peer-reviewed medical articles as well as the author of several chapters in Infectious Disease textbooks.

  • Jacopo Andreose

    Head of International

    Jacopo Andreose is Head of the International Region, responsible for the business in Asia-Pacific, Africa, Middle-East, Latin America and Russia-CIS.

    He joined ViiV Healthcare in 2015 as VP, Healthcare Strategy, coming from GSK where he was leading the Global Commercial dermatology organization. Jacopo brought to ViiV Healthcare extensive experience in specialty areas such as Immunology, HIV and oncology, gained through a number of senior commercial roles in Abbott and BMS. Jacopo has a PhD in Pharmacology from the University of Milan, Italy and a Master of Management in International Marketing from the Norwegian Business school in Oslo, Norway.​​

     

     

  • Tim Tordoff

    Head of Europe

    Tim Tordoff is Head of Europe at ViiV Healthcare.

    Tim joined ViiV Healthcare from GSK where most recently he held the position of VP Service Development for GSK Core Business Services. This role enabled Tim to build on and broaden his capabilities in programme and service leadership and create significant value for the GSK business through a major initiative to deliver more customer focused services. 

    With a strong commercial background, Tim joined GSK in 1993. He held a number of roles of increasing responsibility across the company’s UK and European organisations in both commercial and R&D roles. Between 2005-2008 Tim served as General Manager, GSK Ireland which included the HIV portfolio among his responsibilities; during his time in this role Tim drove a step change in government understanding and engagement with GSK. In his subsequent appointment as VP, Primary Care in 2008 Tim was instrumental in focusing the customer facing teams on launch and growth brands in a rapidly changing UK customer environment. This led to the successful launch of four medicines in 18 months.

  • Mark Cockett

    Vice President, Head of Discovery

    Currently lead for the ViiV Healthcare discovery organisation, Mark Cockett is responsible for delivering new HIV drug candidates that are aligned to future medical needs into clinical development; and providing research support for clinical development assets as they progress in the clinic.

    Mark joined ViiV Healthcare in February this year with the acquisition of Bristol-Myers Squibb (BMS) HIV pipeline assets. Previously Mark was VP of Discovery Infectious Diseases at BMS (2008-2016), responsible for delivery of antiviral therapeutics into the pipeline. His team at BMS has delivered marketed products targeting HIV, HBV and HCV as well as the pipeline of HIV drugs recently acquired by ViiV Healthcare. Prior to this at BMS Mark was VP, Applied Genomics (2003-2008) and Executive Director, Functional Genomics (2000-2003) and in those roles led a team that supported all therapeutic areas with genomics technologies and bioinformatics.

    Before joining BMS, Mark worked for 7 years in the Neuroscience group at Wyeth, ultimately as Director, molecular & cell biology, and for 10 years in the biotech industry for Celltech PLC, where he worked on mammalian gene expression technology and in oncology. Whilst at Celltech he obtained his Ph.D. in collaboration with the Strangeway Research Laboratory, Cambridge, UK working on the involvement of matrix metalloproteinases in tumour cell invasion.

    Mark has published over 50 peer reviewed articles in the field of recombinant gene expression in mammalian cells; the biochemistry and function of several matrix metalloproteinase enzymes and their role in disease; in the field of heterotrimeric G protein signaling; Genomics in the pharmaceutical industry and most recently several virology publications.

  • Gregory Reinaud

    Head of Global Commercial Strategy

    Gregory Reinaud is Head of Global Commercial Strategy, including global product strategy for new and marketed products and commercial portfolio management. Before taking the role of Country Manager in Canada in 2011, where he successfully led the team for three years with a key focus on the launches of Tivicay and Triumeq, Greg started his career at ViiV Healthcare as the Executive Manager to Dominique Limet and the VET, at the creation of ViiV Healthcare

    Prior to joining ViiV Healthcare, he was a management consultant focused on healthcare with McKinsey & Co. He also worked at the UK Treasury and MTV. Greg is a graduate in Natural Sciences from Cambridge University in the UK and holds an MBA from INSEAD.​​

  • Jerome Andries

    CFO

    As CFO, Jerome Andries is accountable for the ViiV Healthcare Finance, Business Development and Business Partners function which provides a diverse range of business capabilities and technical finance support across the company, including oversight of IT and Supply Chain.

    Jerome joined ViiV Healthcare from GSK where he held the position of VP, Business Development for the Emerging Markets region. Most recently, he took on the additional responsibility for finance for the Middle-East Africa region. Prior to joining GSK, Jerome was the CFO and VP, Finance for Lilly’s European Operations. He spent most of his career in the pharmaceutical industry where he held a number of finance and business development posts at Eli Lilly and Hoechst Marion Roussel across Europe, the Middle East and Asia.

    Jerome graduated in Economics from the University of Nice before going on to gain a post-graduate degree in auditing from the University of Paris–Dauphine in 1992.

  • Jocelyn Brown

    Global Head of HR

    Jocelyn Brown is our global Head of HR and joined ViiV Healthcare from GSK in 2016.  

    Jocelyn developed her career at GSK since 2002, where she held various HR positions of increasing seniority working in UK Pharma, Consumer Healthcare, GMS, and the HR Talent and Leadership Centre of Excellence.  In her most recent role prior to joining ViiV Healthcare Jocelyn supported several GSK Corporate Executive Team members and their leadership teams to deliver change, capability building and talent programmes across the Global Ethics and Compliance and Communications and Government Affairs functions, as well as Global Corporate Development, Corporate Secretariat and the Office of the CEO.

    Jocelyn is responsible for delivering HR strategy across ViiV Healthcare, supporting leaders and employees to continue guiding the business through a continued period of growth, develop capability and talent underpinned by our company’s unique culture.

    Jocelyn holds a degree in History & Management Studies from the University of Glasgow, Scotland.